Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS [Phase 1]
A Phase 1 study evaluating CG-806 in patients with relapsed or refractory acute myeloid leukemia or higher-risk myelodysplastic syndromes ha…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
This completed clinical trial evaluated myeloablative hematopoietic progenitor cell transplantation in pediatric patients with chronic myelo…
-
CLINICAL_TRIALS trial_result · 2025-03-07Clinical Trial Update: APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) [Phase 1]
A Phase 1 trial of APR-548 in combination with azacitidine for TP53-mutant myelodysplastic syndromes was terminated. Results were posted in …
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: Efficacy and Safety of Luspatercept: a Study by Fondazione Italiana Sindromi Mielodisplastiche
A completed clinical trial evaluating the efficacy and safety of luspatercept in myelodysplastic syndromes.
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) [Phase 2, Phase 3]
A study evaluating imetelstat (GRN163L) in IPSS low or Intermediate-1 risk myelodysplastic syndrome (MDS) across Phase 2/Phase 3, status ACT…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-02-14Clinical Trial Update: Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) [Phase 2, Phase 3]
This update reports results from a Phase 2/Phase 3 study of Imetelstat (GRN163L) in participants with IPSS low- or intermediate-1 risk myelo…
-
CLINICAL_TRIALS trial_result · 2025-02-13Clinical Trial Update: Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents [Phase 1]
Phase 1 trial of fostamatinib for lower-risk myelodysplastic syndromes or chronic myelomonocytic leukemia after failure of hypomethylating a…
-
CLINICAL_TRIALS trial_result · 2025-02-10Clinical Trial Update: A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome [NA]
This clinical trial update reports results for a telehealth advance care planning intervention targeting older patients with Acute Myeloid L…
-
CLINICAL_TRIALS trial_result · 2025-02-06Clinical Trial Update: Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes [Phase 3]
A completed Phase 3 trial compared standard care with a combination of growth factor agents in patients with low-risk myelodysplastic syndro…
-
CLINICAL_TRIALS trial_result · 2025-02-04Clinical Trial Update: Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes
A completed clinical trial update investigates how immune and metabolic pathways interact in myelodysplastic syndromes.
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: GITMO AML/MDS-Relapse Registry Study
The GITMO AML/MDS-Relapse Registry Study has completed.
-
CLINICAL_TRIALS trial_result · 2025-01-23Clinical Trial Update: SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) [Phase 1, Phase 2]
Clinical trial update reporting completion and posted results for SGI-110 (guadecitabine) in patients with myelodysplastic syndromes, chroni…
-
CLINICAL_TRIALS trial_result · 2025-01-13Clinical Trial Update: Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 trial evaluating the addition of ivosidenib to chemotherapy for IDH1-mutant relapsed or refractory acute myeloid leukemia, including…
-
CLINICAL_TRIALS trial_result · 2025-01-07Clinical Trial Update: Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating the combination of bortezomib and low-dose cytarabine in high-risk myelodysplastic syndromes has been co…
-
CLINICAL_TRIALS trial_result · 2025-01-07Clinical Trial Update: Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia [Phase 1]
Phase 1 clinical trial update on the combination of ipilimumab and decitabine in patients with relapsed or refractory myelodysplastic syndro…
-
CLINICAL_TRIALS trial_result · 2024-12-20Clinical Trial Update: Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients [Phase 2]
Phase 2 trial evaluating posaconazole prophylaxis during ATG treatment in patients with aplastic anemia or myelodysplastic syndromes; the st…
-
CLINICAL_TRIALS trial_result · 2024-12-19Clinical Trial Update: A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS [Phase 1, Phase 2]
A Phase Ib/II multicenter open-label study of bemcentinib (BGB324) in acute myeloid leukemia or myelodysplastic syndromes has completed and …
-
CLINICAL_TRIALS trial_result · 2024-12-16Clinical Trial Update: Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents [Phase 2]
A Phase 2 trial update evaluating low-dose deferasirox in adults with low-risk myelodysplastic syndromes who are resistant or relapsing afte…
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies [Phase 1]
Phase 1 clinical trial studying tagraxofusp in pediatric patients with CD123-expressing hematologic malignancies is currently recruiting, sp…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML [Phase 2]
Phase 2 clinical trial evaluating CD34-selected allogeneic hematopoietic stem cell transplantation with myeloablative conditioning plus CD8+…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion [Phase 2]
Phase 2 study in Japanese patients with IPSS-R very low/low or intermediate risk myelodysplastic syndromes not requiring red blood cell tran…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy [Phase 2]
Phase 2 trial investigating CPI-613 (devimistat) in patients with previously treated myelodysplastic syndromes. The study was terminated and…
-
CLINICAL_TRIALS trial_result · 2024-10-15Clinical Trial Update: Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies [Phase 2]
Phase 2 trial evaluating post-transplantation bendamustine and cyclophosphamide in refractory myeloid malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2024-10-02Clinical Trial Update: A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) [Phase 2]
Phase 2 study of oral decitabine/cedazuridine in combination with magrolimab for intermediate- to very high-risk myelodysplastic syndromes w…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS [Phase 1]
Phase I study of CYC140, a PLK-1 inhibitor, in advanced leukemias and myelodysplastic syndromes has been terminated.